1) Tavecchio S, Angileri L, Pozzo Giuffrida F, et al. Efficacy of dupilumab on different phenotypes of atopic dermatitis : One-year experience of 221 patients. J Clin Med. 2020 ; 9 : 2684.
2) Barbarot S, Wollenberg A, Silverberg JI, et al. Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis : Combined results of four randomized phase 3 trials. J Dermatolog Treat 2022 ; 33 : 266-77.
3) Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis : A randomized clinical trial. JAMA Dermatol. 2021 : 157 ; 1047-55.
4) Deleuran M, Thaci D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020 ; 82 : 377-88.
5) Saeki H, Ohya Y, Furuta J, et al. Executive summary : Japanese guidelines for atopic dermatitis (ADGL) 2021. Allergol Int. 2022 ; 71 : 448-58.
6) Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017 ; 171 : 217-28.
7) Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis : Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol. 2020 ; 82 : 1328-36.
8) Bao L, Mohan GC, Alexander JB, et al. A molecular mechanism for IL-4 suppression of loricrin transcription in epidermal keratinocytes : Implication for atopic dermatitis pathogenesis. Innate Immun. 2017 ; 23 : 641-7.
9) Cabanillas B, Novak N. Atopic dermatitis and filaggrin. Curr Opin Immunol. 2016 ; 42 : 1-8.
10) Oriente A, Fedarko NS, Pacocha SE, et al. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther. 2000 ; 292 : 988-94.
11) Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002 ; 347 : 1151-60.
12) Albanesi C, Fairchild HR, Madonna S, et al. IL-4 and IL-13 negatively regulate TNF-α- and IFN-γ-induced β-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS) -1, and SOCS-3. J Immunol. 2007 ; 179 : 984-92.
13) Brauweiler AM, Goleva E, Leung DYM. Th 2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6). J Invest Dermatol. 2014 ; 134 : 2114-21.
14) Callewaert C, Nakatsuji T, Knight R, et al. IL-4Rα blockade by dupilumab decreases Staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis. J Invest Dermatol. 2020 ; 140 : 191-202. e7.
15) Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab : A meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018 ; 78 : 62-69. e1.
16) Beck LA, Silverberg JI, Simpson EL, et al. Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis : Results from five randomized clinical trials. J Eur Acad Dermatol Venereol. 2021 ; 35 : e130-133.
17) Cork MJ, Eckert L, Simpson EL, et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis : analysis of pooled data from the randomized trials SOLO 1 and SOLO2. J Dermatolog Treat. 2021 ; 31 : 606-14.
18) Blauvelt A, Rosmarin D, Bieber T, et al. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions : data from phase III clinical trials. Br J Dermatol. 2019 ; 181 : 196-7.
19) Jo CE, Finstad A, Georgakopoulos JR, et al. Facial and neck erythema associated with dupilumab treatment : A systematic review. J Am Acad Dermatol. 2021 ; 84 : 1339-47.
20) Muzumdar S, Skudalski L, Sharp K, et al. Dupilumab facial redness/dupilumab facial dermatitis : A guide for clinicians. Am J Clin Dermatol. 2022 ; 23 : 61-7.
21) Waldman RA, DeWane ME, Sloan B, et al. Characterizing dupilumab facial redness : A multi-institution retrospective medical record review. J Am Acad Dermatol. 2020 ; 82 : 230-2.
22) Quint T, Brunner PM, Sinz C, et al. Dupilumab for the Treatment of Atopic dermatitis in an Austrian cohort-real-life data shows rosacea-like folliculitis. J Clin Med. 2020 ; 9 : 1241.
23) Krakowski AC, Senft SC, Heymann WR. Demodex folliculitis and recent dupilumab administration. Pediatrics. 2021 ; 147.
24) Uchida H, Kamata M, Egawa S, et al. Newly developed erythema and red papules in the face and neck with detection of demodex during dupilumab treatment for atopic dermatitis improved by discontinuation of dupilumab, switching to upadacitinib, or treatment with oral ivermectin : A report of two cases. J Eur Acad Dermatol Venereol. 2023 ; 37 : e300-e302.
25) Kozera E, Stewart T, Gill K, et al. Dupilumab-associated head and neck dermatitis is associated with elevated pretreatment serum Malassezia-specific IgE : a multicentre, prospective cohort study. Br J Dermatol. 2022 ; 186 : 1050-2.
26) Linder C, Shourick J, Touhouche AT, et al. Analysis of non-responders to dupilumab in clinical practice : a cohort study. J Eur Acad Dermatol Venereol. 2021 ; 35 : e192-e194.